Oxidized HDL Increase Risk of Heart Failure with Preserved Ejection Fraction: Study

Every standard deviation (SD) increase in nHDLox was associated with a 67% greater risk of HFpEF when compared to the individuals without heart failure. These findings underline the potential of nHDLox as a biomarker for early detection of HFpEF and emphasize its importance in guiding future therapeutic strategies.

HFpEF, is a heterogeneous clinical syndrome with limited treatment options. Current approaches primarily focus on symptom management rather than targeting the underlying causes. The discovery of impaired HDL antioxidant function as a risk factor opens new avenues for addressing HFpEF through early intervention.

Overall, the findings of this research suggest that restoring or improving HDL function could serve as a promising therapeutic target. Strategies to reduce oxidative stress and inflammation may hold the key to reduce the progression of HFpEF. While further studies and trials are needed to explore the mechanisms and treatment possibilities, this research provides a significant step forward in understanding the complex biology of heart failure.

Reference:

Sasko, B., Kelesidis, T., Kostin, S., Scharow, L., Mueller, R., Jaensch, M., Wintrich, J., Christ, M., Ritter, O., Ukena, C., & Pagonas, N. (2025). Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection fraction. Clinical Research in Cardiology: Official Journal of the German Cardiac Society. https://doi.org/10.1007/s00392-024-02583-3